Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2009

View Archived Issues

Liposomal influenza M2e vaccine shows efficacy in immunosuppressed mice

Exebryl-1 shows promise as a disease-modifying drug for the treatment of Alzheimer's disease

Differenting Alzheimer's disease and Lewy bodies dementia with ioflupane (I123) SPECT

Provectus initiates phase II PH-10 trial with new dosing regimen in psoriasis

Tekturna HCT approved in patients likely to need multiple blood pressure drugs

Vernalis selects new oncology development candidate, V-158411

FDA grants fast track status for apaziquone for bladder cancer

Swissmedic grants marketing authorization to Debiopharm for Moapar

Idenix completes proof-of-concept study for IDX-184 in hepatitis C virus

Oramed reports results from phase I oral insulin capsule study in type 1 diabetes

R-Tech Ueno completes phase I RK-023 study

Roche describes novel BLT receptor antagonists for the treatment of asthma, COPD

Wyeth patents novel K(V) potassium channel blockers

Sterix patent claims 17beta-HSD3 inhibitors

GlaxoSmithKline discovers novel P2X7 receptor antagonists

Preclinical data lead MABT-5102-A into clinical evaluation

BioCancell receives Israeli approval to initiate a phase I/IIa clinical trial of BC-819

Putative biomarkers not affected by semagacestat or solanezumab in AD patients

Wyeth stockholders approve adoption of merger agreement with Pfizer

MediciNova to initiate development of MN-221 for treatment of COPD exacerbations

MacroGenics initiates phase II PARADIGM clinical trial of MGAWN-1 for West Nile virus

Forma and LLS form partnership to develop novel blood cancer therapeutics

Health Canada approves Stem Cell's modified REGENESIS phase IIb trial of NTx-265

Archemix and Dicerna sign agreement for designing aptamer-DsiRNA therapeutics

Chugai files NDA in Japan for R-744 for renal anemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.